A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)

drug protocol number

D9185C00001

drug sponsor

AstraZeneca

drug study

Tozorakimab (MEDI3506)

drug trial site

King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase